BioSpace News Archive

Kaleido Biosciences, Inc., a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health announced the initiation of a controlled clinical study evaluating Microbiome Metabolic Therapy candidate KB109 added to Supportive Self-Care for outpatients who are positive for SARs-Cov-2 infection with mild-to-moderate COVID-19.

3M reported sales information for the month of April 2020. The company withdrew its full-year 2020 outlook on April 28, 2020, due to the uncertain impact of the COVID-19 pandemic, and committed to provide monthly updates until it is better able to forecast future performance.

TransEnterix, Inc., a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, announced its operating and financial results for the first quarter of 2020.

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, announced full enrollment of its pivotal Phase 3 SERENITY trials evaluating BXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorder.

VBL Therapeutics announced financial results for the first quarter ended March 31, 2020, and provided a corporate update.

Microbix Biosystems Inc., an award-winning life sciences innovator and exporter, reports results for its second quarter and first half of fiscal 2020 ended March 31, 2020, with the timing of product shipments to customers affecting Q2 results.

Innate Pharma SA announced that it will present new data on its lead partnered asset, monalizumab, at the ASCO20 Virtual Scientific Program being held May 29-31, 2020.

Verona Pharma plc announces that it has received written comments from the U.S. Food and Drug Administration in response to its End-of-Phase 2 briefing package for nebulized ensifentrine as a maintenance treatment for chronic obstructive pulmonary disease.

Lysogene, a Phase 3 gene therapy platform company targeting central nervous system diseases, announced the upcoming abstract selected for an oral presentation at the virtual 23rd ASGCT Annual Meeting and presentations at the EFGCP and NTSAD family conference.

Ultrasonic scalpels find use in simultaneous coagulation and cut of tissues through utilization of ultrasonic vibrations, these medical devices are used for vessels and tissues up to 5 mm in size.